Table 1

Cytotoxicity of single agent oxaliplatin in cisplatin-resistant cell lines

Cell lineExtent of resistanceOriginAssayDuration of exposureOxaliplatin IC50m)References
ParentalResistant
Cervix
 KB 3-1KBCPCisplatin × 20HumanMTT96 h2.27 ± 1.212
Ovarian
 A2780A2780ECisplatin × 80HumanMTT96 h4.7 ± 0.912
A2780/CPCisplatin × 18HumanMTT72 h0.3313
A2780/CPCisplatin × 20HumanCell count72 h25.4 ± 5.227
A2780C13Cisplatin × 13HumanCell count48 h13.5 ± 4.619
A2780C10Cisplatin × 8HumanMTT72 h0.19 ± 009100
A2780C25Cisplatin × 12HumanMTT72 h2.2 ± 0.14100
A2780C70Cisplatin × 32HumanCell count72 h6.7 ± 0.227
Lung
 PC-9PC9/CDDPCisplatin × 11HumanCell count72 h13.3 ± 0.718
 PC-14PC14/CDDPCisplatin × 10HumanCell count72 h14.3 ± 218
Ovarian
 A2780A2780/LOHPOxaliplatin × 4HumanMTT72 h0.913
Leukemia
 L1210L1210/CPCisplatin × 11MurineMTT72 h0.113
L1210/DACHOxaliplatinMurineMTT72 h1413
Colon
 HT29HT29-5-FU5-FU × 6HumanCell count48 h1.7 ± 0.819
Breast
 MCF-7MCF-7/mdrDoxorubicin × 2HumanCell count48 h12.2 ± 9.119